Hongene Biotech presents a whitepaper on addressing supply chain complexities in nucleic acid therapeutics (NAT) manufacturing through vertical integration.
Key Insights:
- Industry Challenges: Fragmented supply chains struggle with inefficiency and inconsistency, failing to meet the growing demand for NATs (mRNA, siRNA, ASO, CRISPR sgRNA).
- Proposed Solution: A vertically integrated CDMO offers an end-to-end solution from raw materials (nucleosides, phosphoramidites, lipids, enzymes, etc.) to drug substance and drug product, optimizing quality, cost, and timelines.
-
Key Benefits:
- A single quality system with end-to-end traceability
- Seamless processes that eliminate tech transfer bottlenecks
- Accelerated development and commercialization
- Choosing a CDMO: Key criteria include full-spectrum capabilities, regulatory readiness, scalable capacity, and technical expertise.
- Hongene's Role: With in-house raw material production, cGMP facilities, and next-gen technologies (e.g., chemoenzymatic ligation), it provides agile and commercially scalable solutions for both biotechs and large pharma.
(To explore the full vertical integration strategy, case studies, and implementation details, download the complete whitepaper.)